Application of deacetylase SIRT2 and medicine for regulating and controlling RNA virus infection

By identifying the regulatory role of SIRT2 in RNA virus infection, using siRNA or AGK2 of SIRT2 to inhibit its expression or activity, the problem of over-activated antiviral response is solved, effective treatment of RNA virus infection is achieved, and damage to the body is reduced risk.

CN119082287APending Publication Date: 2024-12-06XINXIANG MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411200628.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, SIRT2 is not used clearly in the treatment of RNA virus-related diseases, and excessive activation of the antiviral innate immune response will cause damage to the body, and a method is needed to regulate the intensity and duration of the antiviral response.

Method used

Through studies, SIRT2 is found to be an important positive regulator of RIG-I and VISA-mediated signaling pathways. The siRNA of SIRT2 or the specific inhibitor AGK2 is used to limit the over-activation of the antiviral innate immune response and inhibit the expression or activity of SIRT2. To regulate antiviral responses associated with RNA virus infection.

Benefits of technology

Effectively reduce the antiviral innate immune response induced by RNA virus infection, reduce tissue damage to the body, and provide a method to inhibit excessive activation of antiviral innate immune response response in clinical practice, ensuring sufficient antiviral ability and reducing at the same time. Unnecessary tissue damage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082287A_ABST
    Figure CN119082287A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to application of deacetylase SIRT2 and a medicine for regulating RNA virus infection. Excessive or sustained activation of an innate immune response induced by anti-viral infection causes damage to organs or tissues of a body, and therefore, it is necessary to develop a drug capable of specifically regulating the intensity and duration of the immune response. The SIRT2 can enhance the innate immune signal pathway triggered by the RNA virus or cytoplasm dsRNA. The SIRT2 knock-down or SIRT2 inhibitor can reduce the antiviral innate immune response to the RNA virus, so that the intensity of the antiviral innate immune response can be flexibly adjusted clinically, and unnecessary tissue damage is reduced while enough antiviral ability is maintained.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of deacetylase SIRT2 and drugs for regulating RNA virus infection. Background Art

[0002] The antiviral innate immune response is a double-edged sword. Although appropriate antiviral innate immune response can help the body resist the invasion of pathogenic microorganisms, excessive or continuous activation of the antiviral innate immune response can damage the body's organs or tissues. For example, excessive activation of the antiviral innate immune response can cause a large number of cytokines (such as IL-6, TNF-α, etc.) and inflammatory mediators to be released sharply in a short period of time, forming a "cytokine storm". This violent inflammatory response can damage the blood vessel wall, cause tissue damage, organ dysfunction, and even endanger life. For another example, the inflammatory response caused by the continuous antiviral innate immune response will not only directly damage the tissues at the site of infection, but may also affect organs far away from the site of infection, such as the lungs, heart, and kidneys, through systemic reactions, leading to multiple organ dysfunction syndrome (MODS). In addition, excessive immune response may also induce autoimmune diseases, further exacerbating the condition. Therefore, the intensity and duration of the activation of the antiviral innate immune response need to be strictly and accurately regulated to avoid causing damage to the body. The corresponding clinical applications require: First, in-depth research on the molecular mechanisms of antiviral innate immune responses, identification of key signaling pathways, regulatory nodes in transcription factors and cytokine networks, and provision of targets for intervention. Secondly, the development of drugs that can specifically regulate the intensity and duration of immune responses. For example, antibody drugs and immunosuppressants for cytokine storms aim to reduce unnecessary tissue damage while maintaining sufficient antiviral capabilities. Thirdly, taking into account the differences in immune responses between individuals, explore individualized treatment plans based on factors such as the patient's genetic background and immune status to achieve more precise medical interventions.

[0003] Activation of the innate immune system relies on the recognition of conserved microbial components known as pathogen-associated molecular patterns (PAMPs) by cellular pattern recognition receptors (PRRs). Viral nucleic acids, including RNA and DNA, are the major PAMPs produced by viral infection. During viral infection, Toll-like receptor 3 (TLR3) recognizes extracellular viral RNA, while intracellular viral RNA is mainly recognized by retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), including RIG-I (also known as Ddx58) and melanoma differentiation-associated gene 5 (MDA5, also known as Ifih1 or Helicard). Both RIG-I and MDA5 are members of the helicase family, with two caspase recruitment domains (CARDs), a DExD / H-box helicase domain, and a C-terminal domain (CTD). In general, RIG-I preferentially binds to short 5'-triphosphate (5'-ppp) dsRNA and plays a key role in host defense against Sendai virus (SeV), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), and influenza virus. Meanwhile, MDA5 has been shown to be essential in recognizing long dsRNA and encephalomyocarditis virus (EMCV). Upon RNA binding, RIG-I and MDA5 recruit the same CARD-containing adaptor protein VISA (also known as IPS-1, CARDIF, or MAVS), which in turn assembles prion-like polymers and serves as a platform for recruiting and phosphorylating downstream signaling proteins TBK1 and IKKi, leading to the activation of IRF3 and NF-κB, and ultimately inducing type I interferons (IFNs), proinflammatory cytokines, and other antiviral genes.

[0004] RIG-I maintains a self-inhibited state in resting cells, and the binding of dsRNA induces its activation, conformational changes, and release of CARDs. The activation of RIG-I is regulated by a series of post-translational modifications, including phosphorylation, ubiquitination, sumoylation, ISGylation, glutamylation, and acetylation. The classical PTMs of RIG-I, such as phosphorylation and ubiquitination, have been extensively studied. For example, phosphorylation of RIG-I by protein kinase Cα (PKCα) and PKCβ or casein kinase II (CK II) keeps RIG-I in a quiescent state, while phosphatases PP1α and PP1γ remove RIG-I phosphorylation and initiate its activation. Meanwhile, several E3 ubiquitin ligases, such as TRIM25, TRIM4, and RNF135, and deubiquitinating enzymes, such as CYLD, USP21, and USP3, have been identified to regulate RIG-I ubiquitination and play a role in antiviral responses. However, the role of unconventional PTMs in the regulation of RIG-I activity has just been revealed and still needs to be addressed in future studies. It has been demonstrated that RIG-I is acetylated at the CTD in resting cells, which prevents RIG-I from binding to dsRNA and controls RIG-I oligomerization. Upon viral infection, histone deacetylase 6 (HDAC6) directly binds to RIG-I and removes acetylation from RIG-I, leading to activation of RIG-I signaling.

[0005] Recently, increasing evidence has highlighted the important role of Sirtuins (SIRTs) in regulating antiviral innate immune signaling pathways. The seven members of the SIRT family (SIRT1-7) are widely expressed and conserved NAD+-dependent deacetylases that play crucial roles in many biological processes, such as inflammation, metabolism, oxidative stress, cell cycle, lifespan, and apoptosis. The subcellular localization of Sirtuins is diverse, with SIRT1 / 6 / 7 mainly in the nucleus, SIRT2 mainly in the cytoplasm, and SIRT3 / 4 / 5 mainly in the mitochondria. A recent study showed that SIRT1 mediates deacetylation of the DNA binding domain (DBD) of IRF3 / IRF7 and regulates IFN production by affecting their liquid-liquid phase separation. Our previous studies have shown that SIRT1 also interacts with IFI16 and inhibits IFI16-mediated antiviral responses in human cells. In addition, the activation of VISA is regulated by deacetylation catalyzed by SIRT3 as a promoter and desuccinylation catalyzed by SIRT5 as a brake. SIRT2 has been reported to reduce the cGAS-STING pathway by interacting with and deacetyling G3BP1 rather than directly binding to cGAS itself. However, although acetylation is essential for RIG-I activation, the role of Sirtuins in RIG-I activation remains unclear.

[0006] Although a variety of activators and inhibitors have been developed for Sirtuins, and some activators and inhibitors have been explored for clinical application, such as the Sirtuins activator resveratrol, the SIRT1 activator SRT2104 and the SIRT1 inhibitor Ex527 have been studied in the treatment of aging, inflammation, metabolism and tumor related diseases, but the application of SIRT2 in the treatment of RNA virus infection related diseases is still unclear. Summary of the invention

[0007] In order to solve the problem in the prior art that the application of SIRT2 in the treatment of diseases related to RNA virus infection is still unclear, and to achieve the above-mentioned purpose, the present invention adopts the following technical solution.

[0008] Excessive activation of antiviral responses can also cause damage to the body, so strict restrictions are needed. The present invention has found through research that at the cellular level, treatment observations of SIRT2 knockdown, SIRT2 deficiency, and SIRT2 expression inhibitors have determined that SIRT2 is an important positive regulator of RIG-I and VISA-mediated signaling pathways. SIRT2 deficiency inhibits RNA virus-induced transcription of downstream antiviral genes and the inherent antiviral response of mice. SIRT2 promotes antiviral innate immune responses against RNA viruses and cytoplasmic dsRNA by regulating the acetylation of RIG-I. Transitional activation based on antiviral responses can cause damage to the body, so we need to limit the transitional activation of antiviral responses.

[0009] Based on the above reasons, the present invention provides an application of deacetylase SIRT2 for non-disease diagnosis or treatment; the application is the application of deacetylase SIRT2 as a drug target for screening drugs for preventing, alleviating or treating RNA virus infections.

[0010] The above application provided by the present invention can clarify the application of SIRT2 in the treatment of diseases related to RNA virus infection, and proves that SIRT2 can be used in the treatment of diseases related to RNA virus infection.

[0011] The present invention has found through research that the innate immune response induced by viral infection can be limited by siRNA of SIRT2 or AGK2, an expression inhibitor of SIRT2, to prevent the cytokines produced by excessive activation from causing damage to the body. Therefore, the present invention can limit the excessive activation of the antiviral innate immune response by siRNA of deacetylase SIRT2 or AGK2, a specific inhibitor.

[0012] Preferably, the RNA virus includes VSV virus or SeV virus. Both VSV and SeV are RNA model viruses that can infect humans and animals, and can induce activation of the RIG-I-mediated innate immune signaling pathway. Therefore, SIRT2 can be used to regulate the excessive activation of the innate immune response induced by RNA viruses, thereby being used in the treatment of diseases related to RNA virus infection.

[0013] Preferably, the deacetylase SIRT2 limits excessive activation of the antiviral innate immune response through siRNA.

[0014] Preferably, the expression of the deacetylase SIRT2 is inhibited by knocking down the deacetylase SIRT2, thereby limiting the over-activation of the antiviral innate immune response.

[0015] The present invention also provides a method for screening drugs for preventing, alleviating or treating RNA virus infection using the deacetylase SIRT2. The method comprises the following steps:

[0016] The candidate drug is administered to an RNA virus infection model, and the expression level or activity of the deacetylase SIRT2 before and after administration is detected. If the expression level or activity of the deacetylase SIRT2 after administration is lower than the expression level or activity of the deacetylase SIRT2 before administration, it indicates that the candidate drug is a target drug;

[0017] The RNA virus includes VSV virus or SeV virus.

[0018] Based on the above method, the present invention also provides a drug for regulating RNA virus infection obtained by screening according to the above method. The drug includes an expression inhibitor of deacetylase SIRT2 or an activity inhibitor of deacetylase SIRT2, the expression inhibitor of deacetylase SIRT2 includes siRNA; the activity inhibitor of deacetylase SIRT2 includes AGK2.

[0019] AGK2 is a specific inhibitor of SIRT2. The siRNAs are S2 and S3; the sense strand sequence of S2 is shown in SEQ ID NO.34; the negative strand sequence is shown in SEQ ID NO.35; the sense strand sequence of S3 is shown in SEQ ID NO.36; the negative strand sequence is shown in SEQ ID NO.37.

[0020] Preferably, the drug contains the expression inhibitor of SIRT2 or the activity inhibitor of deacetylase SIRT2 as an active ingredient, and is supplemented with pharmaceutically acceptable excipients.

[0021] Preferably, the concentration of the SIRT2 expression inhibitor or the SIRT2 deacetylase activity inhibitor in the drug is 9.5 μM to 10.5 μM. More preferably, the concentration of the SIRT2 expression inhibitor or the SIRT2 deacetylase activity inhibitor in the drug is 10 μM.

[0022] Preferably, the auxiliary material includes any one or more of water, saline, buffer, glycerol and ethanol.

[0023] Preferably, the drug is used to improve multiple organ dysfunction syndrome caused by excessive activation of antiviral innate immune response.

[0024] Preferably, the drug is used to improve autoimmune diseases caused by excessive activation of antiviral innate immune response.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention provides the application of deacetylase SIRT2 and the drug for regulating RNA virus infection. The research results of the present invention show that SIRT2 promotes the innate immune response triggered by RNA virus in vivo, and SIRT2 enhances the innate immune signaling pathway triggered by RNA virus or cytoplasmic dsRNA. SIRT2 deficiency will damage the antiviral innate immune signaling pathway against RNA virus and promote RNA virus infection. SIRT2 deficiency will damage the antiviral innate response of primary immune cells and non-immune cells induced by RNA virus or cytoplasmic dsRNA. Knocking down SIRT2 with siRNA or treating with AGK2, an expression inhibitor of SIRT2, reduces the antiviral innate immune response to RNA virus. Treatment with AGK2 in vivo reduces the production of type I IFN triggered by RNA virus. Therefore, the present invention provides a method for inhibiting the over-activation of antiviral innate immune response by siRNA or specific inhibitor AGK2 of SIRT2 in clinical practice. At the same time, SIRT2 can be used as a target substance for screening drugs for preventing, alleviating or treating RNA virus infection. SIRT2 expression inhibitors can flexibly regulate the intensity of the antiviral innate immune response, thereby reducing unnecessary tissue damage while ensuring sufficient antiviral ability. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The SIRT2 deficiency in the present invention reduces the innate immune response of mice induced by RNA viruses, wherein: Figure 1 Figure A shows intravenous infection with VSV (2×10 7 PFU, n = 4) or SeV (5 × 10 5PFU, n = 5) ELISA of IFN-β and IL-6 in the sera of wild-type (WT) and Sirt2-deficient (KO) mice 6 h later; Figure 1 Panel B shows the wild-type (WT) and Sirt2-deficient (KO) mice intravenously infected with VSV (2×107 PFU, n=3) or SeV (5×10 5 PFU, n = 3) for 24 h, and then the lungs were tested by real-time PCR; Figure 1 Panel C shows wild-type (WT) and Sirt2-deficient (KO) mice (n=6) infected intranasally with SeV (5×105 PFU) for 24 hours; bronchoalveolar lavage fluid (BALF) was collected and subjected to ELISA assay; data represent three independent experiments and are expressed as mean ± SD *, p < 0.05, **, p < 0.01, ***, p < 0.001, ****, p < 0.0001.

[0028] Figure 2 The SIRT2 in the present invention promotes the RNA virus-induced signaling pathway in human cells; wherein, Figure 2 Figure D shows HEK293T cells transfected with an empty vector (Vec) or a plasmid expressing SIRT2, followed by VSV (MOI = 1) ( Figure 2 Figure A in Figure 2 C) or infected with poly(I:C) (1 μg / ml) ( Figure 2 Figure B in the figure, Figure 2 The cells were then lysed for real-time PCR ( Figure 2 Figure A in Figure 2 B) or immunoblotting ( Figure 2 Figure C in the figure, Figure 2 Figure D in the figure); Figure 2 Figure E in Figure 2 shows HEK293T cells transfected with an empty vector (-) or a plasmid expressing SIRT2 (+) and then infected with SeV (MOI = 1) for 8 hours. The cells were then separated into cytoplasmic and nuclear subfractions; immunoblotting assays were performed as indicated; β-actin served as a loading control in all immunoblotting assays. Data represent three independent experiments and are presented as mean ± SD *, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0029] Figure 3 The SIRT2 knockdown in the present invention inhibits the RNA virus-induced signaling pathway; wherein, Figure 3Figure A shows HEK293T cells transfected with Flag-SIRT2, and then transfected with control siRNA (SC) or SIRT2-specific siRNA (S1, S2, S3, and S4); 24 hours after transfection, cells were lysed for immunoblotting (top); PMA-THP1 cells were transfected with control siRNA (SC) or SIRT2-specific siRNA (S1, S2, S3, and S4). 24 hours after transfection, cells were infected with VSV (MOI = 1) for 8 hours, and then immunoblotting was performed (bottom); Figure 3 Figure B in - Figure 3 Figure C shows PMA-THP1 cells transfected with control siRNA (SC) or SIRT2-specific siRNA (S2); 24 hours after transfection, cells were inoculated with VSV (MOI = 1) ( Figure 3 Cells were infected with poly(I:C) or dsRNA (1 μg / ml) ( Figure 3 (C) Transfected cells for 24 hours; supernatants were collected and subjected to ELISA assay; Figure 3 Panel D in the figure shows PMA-THP1 cells transfected with control siRNA (SC) or SIRT2-specific siRNA (S2). 24 hours after transfection, cells were infected with VSV (MOI = 1) for the indicated time. Then cells were lysed for real-time PCR assay; Figure 3 Figure E in - Figure 3 Figure G shows PMA-THP1 cells transfected with control siRNA (SC) or SIRT2-specific siRNA (S2 and S3); 24 hours after transfection, VSV (MOI = 1) ( Figure 3 F in Figure ), or infected cells with poly(I:C) or dsRNA (1 μg / ml) ( Figure 3 Figure E in the figure, Figure 3 G in Figure ) for 8 hours; then the cells were lysed for real-time PCR ( Figure 3 E in Figure ) or immunoblotting ( Figure 3 In the F graph, Figure 3 G in Figure ) determination; Figure 3 Figure H in Figure 2 shows PMA-THP1 cells transfected with control siRNA (SC) or SIRT2-specific siRNA (S2). 24 hours after transfection, cells were infected with VSV (MOI = 1) for the indicated time; cells were then divided into cytoplasmic and nuclear subfractions. Immunoblotting was performed as indicated; β-actin served as a loading control in all immunoblotting assays. Data represent three independent experiments and are expressed as mean ± SD *, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0030] Figure 4The SIRT2 deficiency in the present invention reduces the innate immune response of PMA-THP1 cells induced by RNA viruses; wherein, Figure 4 Panel A shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells infected with VSV (MOI = 1) for 8 h. Cells were lysed for immunoblotting assay; Figure 4 Panel B in the figure shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells infected with GFP-VSV (MOI = 1) for 24 hours, followed by immunofluorescence assay; cell nuclei were stained with DAPI. Scale bar, 500 μm; Figure 4 Figure C in - Figure 4 Figure D shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells treated with VSV (MOI = 1) ( Figure 4 B) or infected with poly(I:C) or dsRNA (1 μg / ml) ( Figure 4 (C) Transfection was performed for 24 hours. The supernatant was collected and subjected to ELISA assay; Figure 4 Panel E in Figure 1 shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells infected with VSV (MOI = 1) for the indicated time. The cells were then lysed for real-time PCR assay; Figure 4 Figure F shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells transfected with poly(I:C) or dsRNA (1 μg / ml) for 8 hours. The cells were then lysed for real-time PCR assay; Figure 4 G graph in - Figure 4 Figure H shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells treated with VSV (MOI = 1) ( Figure 4 G in Figure 1) or infected with poly(I:C) ( Figure 4 H in the figure) were transfected for 8 hours. The cells were then lysed for immunoblot analysis; Figure 4 The I graph in the figure is VSV (MOI = 1) ( Figure 4 Wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells were infected with SIRT2 for the indicated times; the cells were then fractionated into cytoplasmic and nuclear subfractions. Immunoblotting assays were performed as indicated; Figure 4Figure J in Figure 1 shows wild-type (WT) and SIRT2-deficient (KO) PMA-THP1 cells infected with VSV (MOI = 1), or transfected with poly (I:C) or dsRNA (1 μg / ml) for 8 hours; then subjected to native-PAGE and denaturing-PAGE assays; β-actin served as a loading control in all immunoblot assays. Data represent three independent experiments and are expressed as mean ± standard deviation *, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0031] Figure 5 The SIRT2 deficiency in the present invention reduces the innate immune response of PMs induced by RNA viruses, wherein: Figure 5 Panel A in the figure shows wild-type (WT) and Sirt2-deficient (KO) PMs infected with SeV (MOI = 1) for 24 h. The supernatants were collected and subjected to ELISA assay; Figure 5 Panel B shows wild-type (WT) and Sirt2-deficient (KO) PMs infected with VSV (MOI = 1) or transfected with poly(I:C) for 8 hours. The cells were then lysed for real-time PCR assay; Figure 5 Figure C in - Figure 5 Panel D shows wild-type (WT) and Sirt2-deficient (KO) PMs infected with VSV (MOI = 1) or transfected with poly(I:C) for the indicated time. Then native PAGE and denaturing-PAGE analysis were performed; β-actin served as a loading control in all immunoblot assays. Data represent three independent experiments and are presented as mean ± SD *, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0032] Figure 6 The SIRT2 deficiency in the present invention reduces the innate immune response induced by RNA viruses in MEFs cells, wherein: Figure 6 Panel A shows wild-type (WT) and Sirt2-deficient (KO) MEFs infected with SeV (MOI = 1) for 24 h. The supernatants were collected and subjected to ELISA assay; Figure 6 Panel B shows wild-type (WT) and Sirt2-deficient (KO) MEFs infected with VSV (MOI=1) or SeV (MOI=1) for 8 hours. The cells were then lysed for real-time PCR assay; Figure 6 Figure C in - Figure 6 Panel D shows wild-type (WT) and Sirt2-deficient (KO) MEFs infected with VSV (MOI = 1) or SeV (MOI = 1) for the indicated times. Immunoblotting assays were performed as indicated; Figure 6Figure E shows Sirt2-deficient (KO) MEFs transfected with Sirt2 (Sirt2-WT) or its H150Y mutant for 24 hours. Cells were infected with SeV (MOI = 1) for 8 hours and then lysed for immunoblotting; β-actin served as a loading control in all immunoblotting assays. Data represent three independent experiments and are expressed as mean ± standard deviation *, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0033] Figure 7 The SIRT2 deacetylating RIG-I of the present invention, wherein Figure 7 Panel A in Figure 2 shows HEK293T cells transfected with the indicated plasmids and increasing amounts of Flag-SIRT2 (0, 0.5, 1, and 2 μg). 24 hours after transfection, cells were lysed and subjected to immunoprecipitation (IP) and immunoblotting (IB) assays; Figure 7 Figure B in - Figure 7 Panel C shows HEK293T cells transfected with the indicated plasmids; 24 hours after transfection, cells were lysed and subjected to immunoprecipitation (IP) and immunoblotting (IB) assays; Figure 7 Panel D shows HEK293T cells transfected with the indicated plasmids and treated with 10 μM AGK2 or DMSO as a control; 24 hours after transfection, cells were infected with SeV (MOI = 1) for the indicated time. Cells were lysed and subjected to immunoprecipitation (IP) and immunoblotting (IB) assays; Figure 7 Panel E in the figure shows HeLa cells transfected with control siRNA (SC) or SIRT2-specific siRNA (S2). 24 hours after transfection, cells were infected with SeV (MOI = 1) for 8 hours; cells were lysed and subjected to immunoprecipitation (IP) and immunoblotting (IB) assays; Figure 7 Figure F in Figure 1 shows wild-type (WT) and Sirt2-deficient (KO) PMA-THP1 cells infected with SeV (MOI = 1) for 8 hours. Cells were lysed and subjected to immunoprecipitation (IP) and immunoblotting (IB) assays; β-actin served as a loading control in all immunoblotting assays. These data represent three independent experiments.

[0034] Figure 8 The expression inhibitor of SIRT2 in the present invention reduces the antiviral innate immune response against RNA viruses, wherein: Figure 8 Figure A in - Figure 8 Panel B in the figure shows PMA-THP1 cells treated with DMSO or AGK2 (10 μM) for 12 hours, then infected with VSV (MOI = 1), or transfected with poly (I:C) or dsRNA (1 μg / ml) for another 24 hours. The supernatant was collected and subjected to ELISA assay; Figure 8Panel C shows that PMA-THP1 cells were treated with DMSO or AGK2 (10 μM) for 12 h and then infected with VSV (MOI = 1) for the indicated time. The cells were then lysed for real-time PCR assay; Figure 8 Figure D in - Figure 8 Panel E in the figure shows that PMA-THP1 cells were treated with DMSO or AGK2 at the indicated doses for 12 h, and then infected with VSV (MOI = 1), or transfected with poly(I:C) (1 μg / ml) for an additional 8 h; the cells were then lysed for immunoblotting assay; Figure 8 Panel F shows that sex- and age-matched wild-type mice were intraperitoneally (ip) injected with AGK2 (10 mg / kg) 24 hours before SeV (5×10 5 PFU, n=7) infection. ELISA analysis was performed using the serum of the mice 6 hours after SeV infection.

[0035] Fig. 9 The vesicular stomatitis virus in the present invention induces the protein expression of SIRT2. DETAILED DESCRIPTION

[0036] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0037] Example 1

[0038] 1. Instruments, Materials and Reagents

[0039] 1. Experimental animals:

[0040] Wild-type mice were purchased from Zhejiang Weitonglihua Experimental Animal Technology Co., Ltd.

[0041] Sirt2-deficient C57 / BL6 mice were purchased from Cyagen.

[0042] Mice were housed in facilities with access to food and water and maintained under a 12-h light / 12-h dark cycle. All animal procedures were performed in accordance with guidelines approved by the Animal Care Committee of Xinxiang Medical College, China (XYLL-20230009). Age- and sex-matched wild-type and Sirt2-deficient mice were used in the experiments.

[0043] 2. cDNA constructs and reagents:

[0044] Human Sirt2 plasmid was amplified by P-PCR using cDNA from THP1 cells infected with SeV (MOI = 1) for 4 h, and its deletion mutant was constructed by PCR and subcloned into pcDNA3 vector. pIFN-β-Luc, RIG-I, VISA, TBK1, and IRF3 were obtained as described above.

[0045] Among them, THP1 cells came from the Cell Bank of the Chinese Academy of Sciences; pcDNA3 vectors came from Thermo Company.

[0046] The following antibodies were used for immunoblot analysis or immunoprecipitation: anti-Flag, anti-HA, anti-Myc (66004-1-Ig, Proteintech), anti-Sirt2, anti-RIG-I, anti-VISA, anti-p-TBK1, anti-TBK1, anti-p-IRF3, anti-IRF3, anti-p-p65, anti-p65, anti-VSVG, anti-H3, anti-β-tubulin, and anti-β-actin.

[0047] Anti-Flag: F3165, Sigma-Aldrich; Anti-HA: 901515, Biolend; Anti-Myc: 66004-1-Ig, Proteintech; Anti-Sirt2: 19655-1-AP, Proteintech; Anti-RIG-I: A0550, Abclone; Anti-VISA: 14341-1-AP, Proteintech; Anti-p-TBK1: 5483T, Cell Signaling Technology; Anti-TBK1: CSB-PA024154LA01HU, Flarbio; Anti-p-IRF3: 4947, Cell Signaling Technology; Anti-IRF3: 11312-1-AP, Proteintech; Anti-p-p65: 3033, Cell Signaling Technology; anti-p65: 10745-1-AP, Proteintech; anti-VSVG: YM3006, Immunoway; anti-H3: CSB-PA010109LA01HU, Flarbio; anti-β-tubulin: 10068-1-AP, Proteintech; anti-β-actin: 60008-1, Proteintech).

[0048] Poly(I:C) (tlrl-picw), 5'ppp-dsRNA (tlrl-3prna), 3phpRNA (tlrl-hpRNA), and cGAMP (tlrl-nacga23) were obtained from InvivoGen.

[0049] PMA (S1819) was purchased from Beyotime Biotechnology.

[0050] AGK2 (S7577) was obtained from Selleck.

[0051] Protease inhibitor 'cocktail': Roche.

[0052] Protein A / G Plus Agarose Immunoprecipitation Reagent: sc-2003, Santa Cruz.

[0053] SDS sample buffer: S8010, Beijing Solebow Technology Co., Ltd.

[0054] 3. Cells

[0055] 3.1 Human embryonic kidney 293T293T cells (HEK293T cells), human monocytic leukemia cells 1 (THP1 cells)1 and HeLa cells were provided by the Stem Cell Bank of the Chinese Academy of Sciences.

[0056] HeLa cells and HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM). THP1 cells were grown in RPMI 1640 medium.

[0057] The source / formula composition of Dulbecco's modified Eagle's medium (DMEM) is D6546, from Merck; the source / formula composition of RPMI 1640 medium is R8758, from Merck.

[0058] PMA-THP1 cells refer to THP1 cells pretreated with 100 ng / ml PMA for 24 hours. PMA is propylene glycol methyl ether acetate, which is sourced from S1819, Biotime Biotech Co., Ltd.

[0059] All the above cells were cultured in a cell culture incubator at 37° C. and 5% CO 2 by volume, and the cell culture medium was supplemented with 10% FBS (BI Company) in a mass percentage, 4 mM L-glutamine, 100 μg / ml penicillin and 100 U / ml streptomycin.

[0060] 3.2 Preparation of PM cells and MEF cells

[0061] The preparation method of PM cells is as follows: 2.5 ml of 4% Brewersthioglycollate (TG) solution was injected into the peritoneal cavity of mice. Four days later, the mice were killed and the peritoneal cavity was exposed under sterile conditions. The peritoneum was kept intact. 5 ml of pre-cooled PBS was drawn up with a syringe and injected into the peritoneal cavity. The needle was not removed. The peritoneal cavity was gently massaged with fingers, and the aspiration was repeated with fresh pre-cooled PBS. Centrifuge at 1000 rpm for about 5 minutes and remove the supernatant. Cell count. Plated on a 24-well plate, 1×10 cells per well 6 After 6 hours, the non-adherent suspended cells were washed away, and the remaining cells were peritoneal macrophages.

[0062] The preparation method of MEF cells is as follows: C57B16 mice were anesthetized with isoflurane on day 13.5 of maternal gestation and killed by rapid cervical dislocation. The embryos were removed, separated from the uterine horns, and washed three times with 10 ml of PBS without calcium / magnesium. After removing the head and organs, the embryos were washed three times with 10 ml of PBS without calcium or magnesium. The embryos were then minced and 2 ml of trypsin was added to each embryo. The mixture was incubated and gently shaken at room temperature for 15 minutes. Trypsinization was stopped by adding 20 ml of MEF complete medium. Undigested tissue pieces were precipitated to the bottom, the supernatant was removed and centrifuged at low speed of 300 g for 5 minutes. The cell pellet was resuspended in MEF complete medium and plated in a culture flask. Examination on the third day of culture in a cell culture incubator showed a uniform layer of fibroblast-like cells.

[0063] It should be noted that, for the subsequent experiments in the present invention, MEF cells of passages 1 to 5 derived from mouse embryos were used.

[0064] The concentration of PBS is 0.01M, the pH is 7.4, and the source is Beijing Solebow Biological Company.

[0065] The MEF complete medium was Dulbecco's modified Eagle's medium, the source / formulation of which was D6546, from Merck.

[0066] The source of trypsin was PR40020, Proteintech.

[0067] Nuclear extract: The nuclear fraction of a cell. It is prepared as follows:

[0068] Cells were lysed with fresh buffer A (10 mM HEPES, 1.5 mM MgCl2·6H2O, 10 mM KCl, 0.5 mM DTT, 0.1% by volume Nonidet P-40, containing protease inhibitor "cocktail" (Roche), pH 7.9). The cell lysate was placed on ice for 10 minutes and centrifuged at 10,000 rpm for 5 minutes at 4°C to remove cytoplasmic proteins. Nuclear proteins were extracted from the pellet in ice-cold fresh buffer C (20 mM HEPES, 1.5 mM MgCl2·6H2O, 0.42 M NaCl, 0.2 mM EDTA, 25% by volume glycerol, 0.5 mM DTT, containing protease inhibitor "cocktail" (Roche), pH 7.9). Insoluble materials were removed by centrifugation at 10,000 rpm for 5 minutes at 4°C. Protein concentration was determined using a BCA protein assay kit. The separated cytoplasmic and nuclear fractions were added with SDS lysis buffer, boiled at 100°C for 10 min, and then subjected to immunoblot analysis.

[0069] TRIzol reagent: Invitrogen.

[0070] 4. Viruses

[0071] VSV virus, SeV virus and HSV-1 virus are owned by the Key Laboratory of Inflammation and Immunity of Xinxiang City, Henan Province.

[0072] 2. Methods

[0073] 1. Cell culture, transfection and stimulation

[0074] HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) in a cell culture incubator, and 10% FBS was added to the culture medium for culture.

[0075] HEK293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) in a cell culture incubator with 10% FBS added to the culture medium.

[0076] THP1 cells were cultured in RPMI 1640 medium in a cell culture incubator with 10% FBS added to the culture medium.

[0077] When HeLa cells, HEK293T cells, THP1 cells and MEF cells are cultured to the bottom of the culture flask, they are transfected respectively. The specific steps are as follows:

[0078] Transfection of HeLa cells, HEK293T cells, THP1 cells, and MEF cells was performed using Lipofectamine 2000 (Invitrogen) according to the Thermo manufacturer's instructions.

[0079] Cell stimulation: After stimulation with VSV virus or SeV virus for a corresponding period of time, subsequent experiments are carried out.

[0080] 2. Immunoprecipitation and immunoblotting analysis

[0081] Immunoprecipitation and immunoblotting analysis were performed as described above, as follows: After the cells were depleted of culture medium, they were placed on ice, washed once with PBS, and then lysed by adding RIPA buffer (20mM Tris-HCl pH 7.4, 137mM NaCl, 10% glycerol by volume, 1% NP-40 by volume, 1mM pyrophosphate, 2mM Na3VO4, 10mM NaF) (500μl / well) containing a protease inhibitor cocktail (Roche). After lysis on ice for 6 minutes, centrifuge at 12,000rpm for 20 minutes and collect the supernatant in an EP tube. Take 40μl of the supernatant and mix it with 6×SDS sample buffer, boil at 100℃ for 5-10 minutes, and use it as whole cell lysates (WCL) for later use. Add 25% BSA to the remaining supernatant to a final concentration of 0.25% by volume, ProteinA / G resin (30μl) and the corresponding antibodies. After incubation at 4°C for 3-24 hours, the resin was collected by forward and reverse centrifugation at 3000 rpm for 30 seconds, washed three times with RIPA buffer, and the residual liquid was aspirated clean. Then, 20 μl 1× SDS sample buffer was added and boiled at 100°C for 10 minutes for Western blotting detection.

[0082] 3. IRF3 dimerization assay

[0083] Cell extracts were prepared in native lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP40 by volume, 1% protease inhibitor cocktail by mass volume, and 1% orthovanadate by mass volume) at 4 ° C for 30 minutes. The lysate was loaded onto a native PAGE gel (without SDS), pre-run for 60 minutes at 40 mA in an electrophoresis buffer (25 mM Tris-HCl (pH 8.4) and 192 mM glycine, with and without 0.2% deoxycholate by mass volume in the cathode and anode chambers, respectively), and then electrophoresed at 25 mA for 60 minutes. Then, the native gel was soaked in SDS electrophoresis buffer (25 mM Tris (pH 8.3), 250 mM glycine, and 0.1% SDS by mass volume) at room temperature, and subsequent experiments were the same as immunoblotting experiments.

[0084] 4. Real-time PCR

[0085] Total RNA was extracted from cultured HEK293T and THP1 cells according to the instructions of TRIzol reagent. All gene transcripts were quantified by real-time PCR using SYBR Green qPCR Master Mix using 7500 Fast Real-Time PCR System (Applied Biosystems). △△Ct The relative folding induction rate was calculated by the method.

[0086] The primers used for real-time PCR are shown in Table 1.

[0087] Table 1 PCR primer information

[0088]

[0089]

[0090] 5. ELISA

[0091] PMs cells, THP1 cells and MEF cells were transfected with VSV virus, SeV virus or synthetic nucleic acid for 24 hours. Cell culture supernatant was collected and IFN-β and TNF-α content was detected by ELISA according to the company's instructions.

[0092] Among them, IFN-β: PBL Company; TNF-α: Thermo Company.

[0093] Eight-week-old wild-type and Sirt2-deficient mice were intravenously infected with VSV or SeV for 24 hours, and then mouse sera were collected and IFN-β and TNF-α were measured by ELISA according to the company's instructions.

[0094] 6. Interfering RNA

[0095] Sirt2 siRNA was purchased from GenePharma, and the small interfering RNA (siRNA) sequences used are shown in Table 2 .

[0096] Table 2 Small interfering RNA sequence information

[0097]

[0098] Negative control siRNA was also purchased from GenePharma.

[0099] siRNA PMA-THP1 and HeLa cells were transfected using Lipofectamine 2000 according to the Thermo manufacturer's instructions. 24 hours after transfection, cells were used for further experiments.

[0100] 7. Generation of Sirt2 knockout cell lines

[0101] Sirt2- / -THP1 cell lines were generated by the CRISPR-Cas9 system as follows: First, multiple pairs of SgRNAs were designed and synthesized, annealed and connected to SB6665 (Bsa I restriction enzyme interface), transformed, plated, and identified by small extraction. After correct identification, HEK293 cells were transfected at a ratio of 2:1 (Cas9: SgRNA), and genomic DNA was extracted from the cells after 72 hours. PCR was performed as a template, and the products were identified by T7E1 enzyme digestion. The SgRNA with the highest targeting efficiency was screened, and a monoclonal cell line with target gene knockout was established using the limiting dilution method. Oligonucleotides specifically targeting the Sirt2 gene in Table 3 were used.

[0102] Table 3 Oligonucleotides specifically targeting Sirt2 gene

[0103] Oligonucleotide name sequence SEQ ID NO. Oligonucleotide1 5'-CCCGAGAGGTGGGATTAGGGAGG-3' 40 Oligonucleotide2 5'-AGGCCCGAGAGGTGGGATTAGGG-3' 41 Oligonucleotide3 5'-CAAAGTGGCCCAATCCTGACAGG-3' 42 Oligonucleotide4 5'-TGTGAGTCCCCTGTCAGGATTGG-3' 43

[0104] 8. Viruses and infections

[0105] The cells were infected with VSV, SeV and HSV-1 for 1.5 hours, and then washed with PBS and cultured in fresh DMEM medium in a 37°C incubator.

[0106] Age- and sex-matched groups of mice were infected with VSV, SeV, or HSV-1 via syringe via tail vein and intranasal drip. VSV virus titer was determined by plaque formation assay on Vero cells as follows: virus solution of each dilution was inoculated into a monolayer cell culture environment, adsorbed for 2 hours, and then covered with 1.6% wt agarose on the monolayer cells and incubated inverted in a 37°C incubator for 72 hours. After crystal violet staining, the cells were counted.

[0107] The above-described viral infection experiments were used for in vivo studies.

[0108] 9. Luciferase reporter gene analysis

[0109] HEK293T cells were transfected with IFN-β luciferase reporter plasmid and control luciferase plasmid as internal control plus indicated plasmids. Empty control vector was added so that a total of 1 μg of DNA was transfected into each cell well. 24 hours after transfection, cells were lysed and reporter gene activity was analyzed using a dual luciferase reporter gene assay system (Promega).

[0110] 10. Confocal Microscopy

[0111] THP1 cells were fixed with 4% PFA in PBS, permeabilized with Triton X-100, and then blocked with 1% BSA in PBS. Cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI).

[0112] 11. In-situ PLA

[0113] The cells were fixed in 4% PFA by volume in PBS for 15 minutes and washed three times with PBS. Afterwards, the cells were permeabilized on ice for 5 minutes with 0.1% TritonX-100 by volume, washed in PBS, and blocked in 5% BSA by volume in PBS for 1 hour at 37 degrees, and incubated in antibodies at 4°C overnight. The next day, the cells were washed three times with wash buffer (Sigma-Aldrich, DUO82049) and incubated with secondary antibodies at 37°C for 2 hours with PLA probes (SigmaAldrich, DUO92001, DUO92005), and then washed three times with wash buffer. The cells were incubated with Duolink in situ detection reagent red (Sigma-Aldrich, DUO92008) at 37°C for 2 hours. Finally, Nuclei was stained with DAPI and covered on a slide. Images were taken using a NikonA1R microscope and quantitatively analyzed using Image ProPlus 6.0.

[0114] 12. The method of RNA-sequence analysis is as follows:

[0115] Total RNA was extracted from wild-type and Sirt2-deficient MEF cells using Trizol reagent 4 h after SeV stimulation. Library preparation and sequencing were performed by BGI (Shenzhen, China).

[0116] To gain insight into the phenotypic changes, enrichment analysis of differentially expressed genes annotated by GO (http: / / www.geneontology.org / ) and KEGG (https: / / www.kegg.jp / ) was performed by Dr. Tom (https: / / biosys.bgi.com / ). Bonferroni corrected the significance level of terms and pathways by Q-value with a strict threshold (Q-value ≤ 0.05). All RNA-seq data have been deposited in the NCBI database and are publicly available.

[0117] 13. Statistics

[0118] Data are presented as mean ± SD of at least three independent experiments. Statistical comparisons between different treatments were performed using unpaired Student's t-test, and p < 0.05 was considered statistically significant.

[0119] 3. Results

[0120] 1. SIRT2 reduces the innate immune response of mice induced by RNA virus infection

[0121] The present invention studies the effect of SIRT2 on the innate immune response of mice induced by RNA viruses. Figure 1 As shown in Figure A: SIRT2 deficiency leads to reduced secretion of IFN-β and IL-6 in mouse serum upon VSV or SeV infection.

[0122] In addition, quantitative PCR results such as Figure 1 As shown in Figure B: In the lungs of infected mice, SIRT2 deficiency leads to reduced production of Ifnb, Cxcl10, Il6, and Ifit1 and increased amounts of viral RNA.

[0123] In addition, ELISA results such as Figure 1 As shown in Figure C: SIRT2 deficiency also leads to reduced secretion of IFN-β, TNF-α, and IL-6 in mouse bronchoalveolar lavage fluid (BALF) after SeV infection.

[0124] In summary, the above research results show that SIRT2 can reduce the innate immune response triggered by RNA viruses in vivo.

[0125] 2. SIRT2 promotes RNA virus-induced signaling pathways in human cells

[0126] To explore the role of SRIT2 in the signaling pathway induced by RNA viruses or cytoplasmic dsRNA, we first overexpressed SIRT2 in HEK293T cells and then stimulated the cells with VSV infection or poly(I:C) transfection. The results of real-time and immunoblot analysis are shown in Figure 2 Figure A in - Figure 2 As shown in Figure D: SIRT2 positively regulates the host innate immune response induced by RNA viruses or cytoplasmic dsRNA.

[0127] Immunoblotting results Figure 2 As shown in Figure E, consistent with the above results, SIRT2 overexpression increased the nuclear translocation of IRF3 and p65.

[0128] Immunoblotting results Figure 2 As shown, SIRT2 expression was induced by VSV infection in phorbol-12-myristate-13-acetate (PMA)-differentiated THP1 (PMA-THP1, a human macrophage-like cell line) cells.

[0129] Next, four pairs of SIRT2-specific siRNA oligonucleotides (S1-4) were constructed. S2 and S3 effectively inhibited the expression of SIRT2 and were used in the subsequent knockout experiment of PMA-THP1 cells (Figure 3A). Figure 3 Figure B and Figure 3 As shown in Figure C, knockdown of SIRT2 reduced the secretion of IFN-β and TNF-α upon VSV infection or cytoplasmic dsRNA stimulation.

[0130] In addition, quantitative PCR and immunoblotting results were Figure 3 Figure D in - Figure 3 As shown in Figure H, Sirt2-silenced PMA-THP1 cells exhibited suppressed innate immune responses, including the production of IFNb, CXCL10, and TNF-a, phosphorylation of TBK1, IRF3, and p65, and nuclear translocation of IRF3 and p65, compared with control cells transfected with interference siRNA (SC).

[0131] Together, these observations suggest that SIRT2 enhances innate immune signaling pathways triggered by RNA viruses or cytoplasmic dsRNA.

[0132] 2. SIRT2 deficiency impairs RNA virus-induced innate immune responses in PMA-THP1 cells

[0133] The results of immunoblotting experiments were Figure 4As shown in Figure A, SIRT2-deficient PMA-THP1 cells were generated to confirm the effect of SIRT2 on RNA virus-induced signaling pathways.

[0134] The results of immunofluorescence experiments were Figure 4 As shown in Figure B, SIRT2 deficiency significantly increased GFP-VSV infection, indicating that SRIT2 restricts RNA virus infection. Figure 4 Figure C in - Figure 4 As shown in Figure F, SIRT2 deficiency resulted in reduced production of IFN-β, proinflammatory cytokines, and other antiviral proteins after stimulation with VSV or cytoplasmic dsRNA. Figure 4 G graph in - Figure 4 As shown in the J panel, the activation of antiviral signaling pathways, including the phosphorylation of TBK1, IRF3, and p65, the nuclear translocation of IRF3 and p65, and the formation of IRF3 dimers, was impaired by SIRT2 deficiency.

[0135] In conclusion, our results suggest that SIRT2 deficiency impairs antiviral innate immune signaling pathways against RNA viruses and promotes RNA virus infection.

[0136] 3. SIRT2 deficiency impairs RNA virus-induced signaling pathways in primary cells

[0137] To further investigate the role of SIRT2 in RNA virus infection, we isolated primary immune cells from wild-type and SIRT2-deficient mice and assessed the effects of SIRT2 deficiency on host defense against RNA viruses and cytoplasmic dsRNA. Figure 5 As shown in Figure A: After SeV or VSV infection, SIRT2-deficient peritoneal macrophages (PMs) exhibited reduced secretion of IFN-β and proinflammatory cytokines compared with wild-type cells.

[0138] In addition, the results of quantitative PCR and immunoblotting experiments were Figure 5 As shown in Figures B-D, SIRT2 deficiency impairs the host's innate immune response to VSV infection or cytoplasmic dsRNA stimulation in PMs. Figure 5 As shown in (F), SIRT2 deficiency leading to reduced activation of host innate immune signaling pathways was also observed in SeV-infected bone marrow-derived dendritic cells (BMDCs).

[0139] Since antiviral innate immune responses are also induced in non-immune cells, we confirmed the function of SIRT2 in MEFs isolated and cultured from wild-type and SIRT2-deficient mice. Consistent with the findings in primary immune cells, such as Figure 6 Figure A in - Figure 6 As shown in Figure E:

[0140] SIRT2 deficiency impaired the innate immune response triggered by RNA viruses in MEFs. Figure 6 As shown in Figure 5F, the impairment of host defense caused by SIRT2 deficiency was rescued by expression of SIRT2 but not by its deacetylase-deficient H150Y mutant, indicating that SIRT2 is essential for RNA virus-triggered signaling pathways and that deacetylase activity is required for SIRT2 to exert its function during RNA virus infection.

[0141] Together, these data suggest that SIRT2 deficiency impairs innate antiviral responses induced by RNA viruses or cytoplasmic dsRNA in both primary immune and non-immune cells.

[0142] 4. SIRT2 deacetylates RIG-I

[0143] It has been reported that RIG-I is acetylated at its CTD, which renders it inactive. Therefore, we wondered whether SIRT2 promotes the host's antiviral innate immune response against RNA virus infection by deacetylation of RIG-I. To explore this possibility, first, we examined the effect of SIRT2 on RIG-I acetylation. Figure 7 Figure A in - Figure 7 As shown in Figure C, SIRT2 reduced the deacetylation of exogenously or endogenously expressed RIG-I, while the inactive H150Y mutant of SIRT2 did not. Figure 7 As shown in Figure 7D and Figure 7E, SIRT2 knockdown or deletion enhanced RIG-I acetylation.

[0144] In addition, the results of immunoblotting experiments were Figure 7 As shown in Figure G, the SIRT2 inhibitor AGK2 increased the acetylation of RIG-I.

[0145] We further investigated the effect of AGK2 on RIG-I-mediated signaling and found Figure 8 Figure A in - Figure 8 As shown in Figure E; AGK2 inhibited the innate immune response induced by RNA virus or cytoplasmic dsRNA in PMA-THP1 cells. In addition, the ELSIA results are shown in Figure 8As shown in Figure F, pretreatment with AGK2 inhibited SeV-induced IFN-β secretion as detected in mouse sera.

[0146] In conclusion, our findings suggest that SIRT2 deacetylates RIG-I and that SIRT2 inhibitors reduce antiviral innate immune responses to RNA viruses.

[0147] It should be noted that when the present invention involves a numerical range, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.

[0148] Although preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they understand the basic inventive concepts, and all such changes and modifications fall within the scope of the present invention.

Claims

1. Application of deacetylase SIRT2, characterized in that: For diagnosis or treatment of non-diseases; The application is the use of deacetylase SIRT2 as a drug target for screening drugs for preventing, alleviating or treating RNA virus infection.

2. The use according to claim 1, characterized in that: The RNA virus includes VSV virus or SeV virus.

3. A drug for regulating RNA virus infection, characterized in that the drug is obtained by screening the method for screening drugs for preventing, alleviating or treating RNA virus infection using the deacetylase SIRT2 described in claim 1.

4. The drug according to claim 3, characterized in that The method for using the deacetylase SIRT2 to screen drugs for preventing, alleviating or treating RNA virus infection comprises the following steps: The candidate drug is administered to an RNA virus infection model, and the expression level or activity of the deacetylase SIRT2 before and after administration is detected. If the expression level or activity of the deacetylase SIRT2 after administration is lower than the expression level or activity of the deacetylase SIRT2 before administration, it indicates that the candidate drug is a target drug; The RNA virus includes VSV virus or SeV virus.

5. The drug according to claim 4, characterized in that The drug includes an expression inhibitor of deacetylase SIRT2 or an activity inhibitor of deacetylase SIRT2; The expression inhibitor of deacetylase SIRT2 includes siRNA; the activity inhibitor of deacetylase SIRT2 includes AGK2; The siRNAs are S2 and S3; the sense strand sequence of S2 is shown in SEQ ID NO.34; the negative strand sequence is shown in SEQ ID NO.35; the sense strand sequence of S3 is shown in SEQ ID NO.36; the negative strand sequence is shown in SEQ ID NO.

37.

6. The drug according to claim 5, characterized in that The drug has the SIRT2 expression inhibitor or the SIRT2 deacetylase activity inhibitor as an active ingredient and is supplemented with pharmaceutically acceptable excipients.

7. The drug according to claim 6, characterized in that: The concentration of the SIRT2 expression inhibitor or the SIRT2 deacetylase activity inhibitor in the drug is 9.5 μM to 10.5 μM.

8. The drug according to claim 6, characterized in that: The auxiliary materials include any one or more of water, saline, buffer, glycerol and ethanol.

9. The drug according to claim 3, characterized in that The drug is used to improve multiple organ dysfunction syndrome caused by excessive activation of antiviral innate immune response.

10. The drug according to claim 3, characterized in that The drug is used to improve autoimmune diseases caused by excessive activation of antiviral innate immune response.